CUTAQUIG (Octapharma Australia Pty Ltd)
Product name
CUTAQUIG
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
199 (255 working days)
Active ingredients
human immunoglobulin g
Registration type
NCE/NBE
Indication
CUTAQUIG (solution for injection) is indicated for replacement therapy in adults and children in:
- Primary immunodeficiency diseases (PID)
- Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.